- IDEAYA Biosciences reported a successful FDA Type C meeting that set the Phase 3 registrational trial design for IDE849 in extensive stage small cell lung cancer. The company is aiming for a global study of about 400 previously tarlatamab-treated patients, with overall survival and response outcomes at the core of the program.
- The IDE849 program sits within a broader IDEAYA Biosciences effort that includes a global Phase 1 trial, combination work with AstraZeneca's Imfinzi, and IDE161. Together, these programs target DLL3 upregulated tumors where current treatment options and clinical outcomes leave a large unmet need.
- With IDEAYA Biosciences aligning IDE849's Phase 3 design with the FDA, we will assess how this planned trial could influence the overall investment narrative around the company.
Scan beyond IDEAYA Biosciences and line up other oncology-focused opportunities with our curated screener of 17 high quality undiscovered gems that may still be flying under most investors' radars.
What Is IDEAYA Biosciences' Investment Narrative?
To own IDEAYA Biosciences, you have to buy into a fairly concentrated execution story. The business is still loss making, expects revenue to grow quickly from a low base, and is leaning on external funding rather than customer deposits. That means the IDE849 program and uveal melanoma franchise carry real operational weight. The FDA Type C meeting and Phase 3 design in ES SCLC reduce some regulatory uncertainty and give investors a clearer line of sight on trial timelines, but they also lock in a large, capital intensive global study with roughly 400 patients. In the near term, attention likely stays on clinical readouts, cash burn and any signals out of events like the upcoming Wells Fargo conference.
Yet there is a catch in the IDEAYA story once you focus on how that trial spend, existing losses and future funding needs might...
There's only one way to know the right time to buy, sell or hold IDEAYA Biosciences. Head to Simply Wall St's company report for the latest analysis of IDEAYA Biosciences's Fair Value.
Exploring Other Perspectives
Three fair value estimates from the Simply Wall St Community span from US$52.15 to US$617.80 per share for IDEAYA Biosciences, which shows how far apart retail opinions can be. With fresh IDE849 Phase 3 plans and a Wells Fargo conference slot on 8 September 2026, it may be worth reassessing these views and exploring several alternative angles before deciding how IDEAYA fits your portfolio.
To see how other investors are framing the potential of IDEAYA Biosciences, take a look at the 2 other fair value estimates for IDEAYA Biosciences.
Decide For Yourself
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your IDEAYA Biosciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
- See our latest analysis for IDEAYA Biosciences. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate IDEAYA Biosciences' overall financial health at a glance.
Looking For More Investment Ideas Beyond IDEAYA Biosciences?
If the IDEAYA Biosciences story has you thinking about how to round out your watchlist, it can help to scan a wider set of opportunities that share some of the quality traits you might be looking for, whether that is stronger balance sheets, lower perceived risk or potential mispricing.
- If you want to focus on sturdier finances and cleaner leverage profiles, start with a list of solid balance sheet and fundamentals (24 results) that can support growth plans through different market conditions.
- For investors who care most about limiting downside, use the 83 resilient stocks with low risk scores to zero in on businesses that screen well on a broad set of risk checks.
- When you are hunting for situations where fundamentals and price look out of sync, the 49 high quality undervalued stocks can help surface ideas that might deserve a closer look.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com